Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
601 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Belgium 34
602 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
603 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 69
604 Apheresis Allogeneic T-Cell Acute lymphoblastic leukemia Hematology 2026 Standard Therapy Netherlands 21
605 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 70
606 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 68
607 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 16
608 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
609 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
610 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 65
611 Apheresis Autologous Central Nervous System Lymphoma Hematology 2026 Standard Therapy Germany 65
612 Apheresis Autologous Diffuse Large B-cell Lymphoma Hematology 2026 Standard Therapy Germany 45
613 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
614 Apheresis Allogeneic B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 21
615 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 65
616 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
617 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 5
618 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Hungary 57
619 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 30
620 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 37
621 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
622 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 1
623 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 59
624 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 65
625 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 28
626 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Estonia 67
627 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 28
628 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 71
629 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
630 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 73
631 Apheresis Allogeneic Acute Myeloblastic Leukemia Hematology 2026 Standard Therapy Romania 62
632 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 62
633 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 52
634 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 71
635 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 48
636 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 59
637 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 52
638 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 43
639 Apheresis Allogeneic Akut Myeloid Leukemia Hematology 2026 Standard Therapy Turkey 48
640 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Finland 16
641 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 30
642 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy Germany 72
643 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 50
644 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 70
645 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 45
646 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 75
647 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 39
648 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 32
649 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Argentina 34
650 Apheresis Allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 68
651 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 63
652 Apheresis Allogeneic T-Cell Non-Hodgkin lymphoma Hematology 2026 Standard Therapy Argentina 70
653 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Czechia 52
654 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy France 62
655 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 20
656 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 53
657 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
658 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 71
659 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 54
660 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Hungary 36
661 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 47
662 Apheresis Autologus Diffuse Large B-Cell Lymphoma hematology 2026 Standard Therapy Germany 65
663 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 59
664 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 59
665 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 59
666 Apheresis Autologus Diffuse Large B-Cell Lymphoma hematology 2026 Standard Therapy Germany 63
667 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 37
668 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 61
669 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 63
670 Apheresis Allogeneic CMMOL-AML hematology 2026 Standard Therapy Hungary 47
671 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Spain 52
672 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 53
673 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Poland 61
674 Apheresis Allogeneic Other Non-Malignant Disease hematology 2026 Standard Therapy USA 67
675 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Germany 3
676 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 38
677 Apheresis Allogeneic Prolymphocytic Leukemia hematology 2026 Standard Therapy United Kingdom 60
678 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Poland 70
679 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 48
680 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy France 60
681 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy USA 51
682 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Chile 6
683 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 56
684 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy USA 69
685 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy USA 41
686 Apheresis Allogeneic Chronic Myelomonocytic Leukemia hematology 2026 Standard Therapy United Kingdom 66
687 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Italy 65
688 Apheresis Allogeneic Acute Lymphoblastic Leukemia hematology 2026 Standard Therapy Germany 49
689 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy USA 76
690 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Italy 61
691 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Poland 4
692 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy USA 65
693 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Poland 59
694 Apheresis Allogeneic Chronic Myelomonocytic Leukemia hematology 2026 Standard Therapy Germany 50
695 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms hematology 2026 Standard Therapy Poland 69
696 Apheresis Allogeneic Hodgkin Lymphoma hematology 2026 Standard Therapy USA 48
697 Apheresis Allogeneic Prolymphocytic Leukemia hematology 2026 Standard Therapy USA 71
698 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy United Kingdom 55
699 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 59
700 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy United Kingdom 62